Enhancement of atomoxetine serum levels by co-administration of paroxetine

International Journal of Neuropsychopharmacology

Volumn 11, Issue 2, 2008, Pages 289-291

  Paulzen, Michael ^a   Clement, Hans Willi ^b   Gründer, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DULOXETINE; PAROXETINE;

ADULT; ATTENTION DEFICIT DISORDER; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; HUMAN; LETTER; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; STEADY STATE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; PAROXETINE; PROPYLAMINES;

EID: 38949171689     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707008115     Document Type: Letter

References (11)

1. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M (1997). Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Journal of Clinical Psychopharmacology 17, 284-291.
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37, 243-265.
3. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (2002). Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. Journal of Clinical Pharmacology 42, 1219-1227.
4. DeVane CL (2003). Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. Psychopharmacology Bulletin 37 (Suppl. 1), 29-41.
5. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J (2007). CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 46, 242-251.
6. Mitchell PB (1997). Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 17, 390-406.
7. Retz-Junginger P, Retz W, Blocher D, Weijers HG, Trott GE, Wender PH, Rossler M (2002). Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 73, 830-838.
8. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA (2002). Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metabolism and Disposition 30, 319-323.
9. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC, et al. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics 51, 278-287.
10. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA (2003). Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metabolism and Disposition 31, 98-107.
11. Sauer JM, Ring BJ, Witcher JW (2005). Clinical pharmacokinetics of atomoxetine. Clinical Pharmacokinetics 44, 571-590.